TIPE1 promotes cervical cancer progression by repression of p53 acetylation and is associated with poor cervical cancer outcome. (15th November 2018)

• Record Type: Journal Article
• Authors: Zhao, Peiqing; Pang, Xiaoming; Jiang, Jie; Wang, Lianqing; Zhu, Xiaolan; Yin, Yingchun; Zhai, Qiaoli; Xiang, Xinxin; Feng, Fan; Xu, Wenlin
• Is Part Of: Carcinogenesis. Volume 40:Number 4(2019)
• Page Start: 592
• Page End: 599
• Publication Date: 2018-11-15
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgy163
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract : TIPE1 promoted cervical cancer progression by suppressing p53 acetylation both in vivo and in vitro . TIPE1 facilitated cell proliferation and suppressed cisplatin susceptibility in a p53-dependent manner. The expression of TIPE1 was higher in cervical cancer tissues than the paired adjacent non-tumor tissues. The results suggested that TIPE1 serves as an oncogene by restricting p53 activity and predicts poor prognosis in patients with cervical cancer. Abstract: Previous studies have shown that TIPE1 inhibits tumor proliferation and metastasis in certain cancers; however, increased expression of TIPE1 is observed in cervical cancer cell lines and tissues, indicating it might exert a distinctive role in cervical cancer. Cell and xenograft tumorigenicity assays showed that TIPE1 facilitates cervical cancer progression in this study. Further investigation demonstrated that TIPE1 binds to p53 and impairs its activity via inhibition of its acetylation. In addition, TIPE1 promoted cell proliferation and suppressed cisplatin susceptibility in a p53-dependent manner, indicating that TIPE1 facilitates cervical cancer progression primarily through the p53 pathway. TIPE1 expression in clinical samples also demonstrated that its upregulation predicts poor prognosis in patients with cervical cancer. Taken together, the results of this study showed that TIPE1 serves as an oncogene by restricting p53 activity in the development of cervical cancer, suggesting that TIPE1 will provide a new potential target for cervical cancer therapy and can be used as a biomarker to predict patient prognosis.